MARKET

NWBO

NWBO

Northwest Bio
OTCMQB
0.391
-0.004
-0.99%
Opening 11:06 07/15 EDT
OPEN
0.399
PREV CLOSE
0.395
HIGH
0.400
LOW
0.391
VOLUME
268.28K
TURNOVER
105.42K
52 WEEK HIGH
2.150
52 WEEK LOW
0.379
MARKET CAP
473.57M
P/E (TTM)
-6.2277
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NWBO last week (0708-0712)?
Weekly Report · 6h ago
Weekly Report: what happened at NWBO last week (0701-0705)?
Weekly Report · 07/08 12:06
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities
Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes at the 2023 Annual Meeting. Northwest Biotherapeutics is a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers. There was an exceptionally strong vote turnout of 961.7 million votes cast out of 1.2 billion shares.
PR Newswire · 07/03 15:56
Weekly Report: what happened at NWBO last week (0624-0628)?
Weekly Report · 07/01 12:07
Weekly Report: what happened at NWBO last week (0617-0621)?
Weekly Report · 06/24 12:17
Weekly Report: what happened at NWBO last week (0610-0614)?
Weekly Report · 06/17 12:05
Weekly Report: what happened at NWBO last week (0603-0607)?
Weekly Report · 06/10 12:08
Weekly Report: what happened at NWBO last week (0527-0531)?
Weekly Report · 06/03 12:12
More
About NWBO
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

Webull offers Northwest Biotherapeutics Inc stock information, including OTCMQB: NWBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NWBO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NWBO stock methods without spending real money on the virtual paper trading platform.